Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients?
D000328:Adult; D003928:Diabetic Nephropathies / Q000628:therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000379:methods*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D014511:Uremia / Q000628:therapy*; D014882:Water-Electrolyte Balance; D014993:Xylitol / Q000009:adverse effects / Q000627:therapeutic use*
D007328:Insulin; D007773:Lactates; D008055:Lipids; D019344:Lactic Acid; D014993:Xylitol